Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan notifications and does not contain financial performance data.
Material Changes
The filing reports an increase in notional interests in Ordinary shares and ADRs for various directors and executives. This increase resulted from the notional re-investment of the dividend paid to shareholders on October 6, 2011. The transaction prices were 1365 pence per Ordinary share and $42.37 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors
- Transaction Type: Notification of notional interest increases under the Performance Share Plan.
- Trigger Event: Re-investment of the dividend paid on October 6, 2011.
- Share Prices: 1365 pence per Ordinary share; $42.37 per ADR.
- Participants: Includes Mr. A P Witty, Dr. M M Slaoui, and other named directors and executives.
- Financial Data: No financial performance metrics are included in this specific filing.